** Shares of Orchestra BioMed Holdings OBIO.O down 11.8% premarket to $2.70 after follow-on prices
** New Hope, Pennsylvania-based firm sells 14.55 mln shares, including ~5.1 mln pre-funded warrants, for $40 mln gross proceeds
** Offering price of $2.75 represents 10.1% discount to stock's last close
** Co plans to use net proceeds to fund its atrioventricular interval modulation (AVIM) therapy for treatment of hypertension and its Virtue Sirolimus AngioInfusion Balloon (SAB) for treatment of atherosclerotic artery disease
** Piper Sandler and TD Cowen are joint bookrunners for offering
** After the bell Thurs, co said secured $70 mln of strategic investments from Ligand Pharmaceuticals LGND.O and Medtronic MDT.N
** While MDT is OBIO's existing partner for AVIM, the cos amended their collaboration agreement to include potential future development of a leadless pacemaker
** OBIO has ~38.6 mln shares outstanding as of Jul 30, per the prospectus, giving it roughly $118 mln market cap through Thurs
** Shares of OBIO fell for third straight day on Thurs, closing down 1.9%, extending YTD loss to 23.5%
** All 7 analysts covering OBIO are bullish and median PT is $12, LSEG data reflects
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.